S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
VTGN · VistaGen Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Vistagen Therapeutics Inc (VTGN)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.20
-0.00
(-1.05%)
● At close: October 21 at 4:00:00 PM EDT
$0.20
+0.01
(+3.62%)
Overnight:
10:59:40 PM EDT
DAY'S RANGE
$0.20
$0.20
$0.20
52-WEEK RANGE
$0.20
$0.19
$5.14
What's happening
- VTGN is down 1.05% today, trading at $0.20. — Live quote
- It's trading within 3% of its 52-week low ($0.19). (Finnhub fundamentals)
- Volume today (4,044) is well below its 3-month average of 9,861,170. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.30 actual vs. $-0.38 estimated (+20.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 5
Sell 1
Strong sell 2
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
VTGN
-70.12%
vs S&P 500
-82.89%
1-YEAR RETURN
VTGN
-95.58%
vs S&P 500
-110.15%
6-MONTH RETURN
VTGN
-67.20%
3-MONTH RETURN
VTGN
-15.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q1 2027)
$-0.30
Est. $-0.38
BEAT +20.5%
2026-04-26 (Q4 2026)
$-0.37
Est. $-0.34
MISS -7.7%
2026-01-26 (Q3 2026)
$-0.45
Est. $-0.50
BEAT +9.2%
2025-10-26 (Q2 2026)
$-0.54
Est. $-0.49
MISS -11.2%
Valuation Measures & Ratios
Enterprise Value4-$8.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.59
Price / Book70.38
EV4 / Revenue-3.20
EV4 / EBITDA—
Profit Margin-2702.64%
Operating Margin-2784.33%
Return on Equity (ROE8)-152.59%
Return on Assets (ROA9)-117.45%
Avg Volume (3M)9,861,170
Quarterly history (5 periods)
| Measure | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $9.8M | $27.9M | $25.5M | $12.8M | $18.1M |
| P/E | -0.15 | -0.41 | -0.41 | -0.24 | -0.41 |
| Price/Book | 0.40 | 0.55 | 0.38 | 0.23 | 0.22 |
| EV/EBITDA | 0.11 | 0.28 | 0.57 | — | — |
| ROE | -271.40% | -132.56% | -92.80% | -93.15% | -54.40% |
| ROA | -185.92% | -103.76% | -76.07% | -76.72% | -47.81% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,750,912
Change from Prior Settlement+38.56%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 504.9% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -2702.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -95.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on VTGN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$13.3M | -$19.5M | -$20.1M | -$15.8M | -$15.1M | -$14.2M | -$12.1M | -$7.9M |
| Net income | -$13.0M | -$18.9M | -$19.4M | -$15.1M | -$14.1M | -$13.0M | -$10.7M | -$6.3M |
| EPS (diluted) | $-0.30 | $-0.45 | $-0.54 | $-0.47 | $-0.46 | $-0.42 | $-0.35 | $-0.22 |
| EPS (basic) | $-0.30 | $-0.45 | $-0.54 | $-0.47 | $-0.46 | $-0.42 | $-0.35 | $-0.22 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $35.7M | $48.6M | $65.1M | $80.9M | $68.9M | $84.3M | $92.3M | $102.5M |
| Total liabilities | $11.3M | $13.0M | $14.1M | $14.6M | $12.2M | $14.0M | $11.2M | $9.5M |
| Stockholders' equity | $24.5M | $35.5M | $50.9M | $66.3M | $56.8M | $70.4M | $81.1M | $93.0M |
| Total current assets | $34.3M | $46.9M | $63.2M | $78.9M | $66.7M | $82.1M | $89.9M | $99.9M |
| Total current liabilities | $11.2M | $12.8M | $13.5M | $13.6M | $11.2M | $12.6M | $9.6M | $7.5M |
| Cash & equivalents | $17.0M | $30.8M | $47.4M | $62.8M | $49.0M | $67.1M | $74.7M | $84.2M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $375.0K | $427.0K | $480.0K | $516.0K | $530.0K | $476.0K | $428.0K | $467.0K |
| Other non-current assets | $392.0K | $393.0K | $392.0K | $405.0K | $472.0K | $454.0K | $477.0K | $498.0K |
| Accounts payable | $1.0M | $1.5M | $1.3M | $1.8M | $486.0K | $653.0K | $1.0M | $715.0K |
| Accrued liabilities | $9.2M | $8.8M | $9.3M | $8.4M | $6.6M | $8.8M | $5.5M | $3.8M |
| Deferred revenue (current) | $234.0K | $1.7M | $2.0M | $2.1M | $2.5M | $2.6M | $2.5M | $2.5M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $44.0K | $40.0K | $40.0K | $39.0K | $29.0K | $29.0K | $28.0K | $27.0K |
| Retained earnings | -$490.3M | -$477.3M | -$461.0M | -$442.1M | -$422.7M | -$407.6M | -$394.0M | -$379.9M |
| Accumulated other comprehensive income (loss) | -$7.0K | -$2.0K | $13.0K | $14.0K | $1.0K | $5.0K | $11.0K | $22.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.7M | -$16.2M | -$17.6M | -$13.8M | -$18.8M | -$10.1M | -$10.3M | -$10.9M |
| Investing cash flow | $0 | -$99.0K | $104.0K | -$94.0K | -$788.0K | $527.0K | -$422.0K | -$7.8M |
| Financing cash flow | $909.0K | -$283.0K | $2.1M | $27.7M | $1.5M | $2.0M | $1.2M | $0 |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $52.0K | $52.0K | $54.0K | $53.0K | $40.0K | $40.0K | $39.0K | $37.0K |
| Share-based compensation | $991.0K | $889.0K | $1.1M | $1.1M | $916.0K | $963.0K | $1.1M | $1.1M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Purchases of investments | $5.6M | $5.7M | $5.9M | $2.0M | $8.7M | $3.9M | $2.4M | $13.2M |
Income statement
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | — | — | — | -$227.0K | $1.1M |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | -$47.8M |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | -$47.8M |
| EPS (diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | — |
| EPS (basic) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | $-7.38 |
| Operating margin | — | — | — | $26.1K | -$4.3K |
| Net margin | — | — | — | $26.1K | -$4.3K |
Balance sheet
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Total assets | $48.6M | $84.3M | $123.7M | $21.1M | $74.6M |
| Total liabilities | $13.0M | $14.0M | $9.4M | $9.0M | $9.9M |
| Stockholders' equity | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M |
| Total current assets | $46.9M | $82.1M | $120.7M | $17.5M | $71.0M |
| Total current liabilities | $12.8M | $12.6M | $5.1M | $4.6M | $5.8M |
| Cash & equivalents | $30.8M | $67.1M | $119.2M | $16.6M | $68.1M |
| Accounts receivable | — | — | — | — | — |
| Property, plant & equipment | $427.0K | $476.0K | $435.0K | $507.0K | $414.3K |
| Other non-current assets | $393.0K | $454.0K | $726.0K | — | — |
| Accounts payable | $1.5M | $653.0K | $1.5M | $2.5M | $2.8M |
| Accrued liabilities | $8.8M | $8.8M | $2.2M | $796.0K | $1.3M |
| Deferred revenue (current) | $1.7M | $2.6M | $791.0K | $714.0K | $1.2M |
| Short-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $40.0K | $29.0K | $27.0K | $7.0K | $6.9K |
| Retained earnings | -$477.3M | -$407.6M | -$356.2M | -$326.9M | -$267.6M |
| Accumulated other comprehensive income (loss) | -$2.0K | $5.0K | $0 | — | — |
Cash flow
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$66.4M | -$42.1M | -$25.8M | -$49.7M | -$45.3M |
| Investing cash flow | -$877.0K | -$13.1M | -$61.0K | -$740.0K | -$200.4K |
| Financing cash flow | $31.0M | $3.2M | $128.4M | -$1.0M | $10.5M |
| Free cash flow | — | — | — | — | -$45.5M |
| Capital expenditures | — | — | — | — | $200.4K |
| Depreciation & amortization | $199.0K | $150.0K | $127.0K | $130.0K | — |
| Share-based compensation | $4.0M | $4.3M | $2.2M | $3.3M | $3.5M |
| Change in accounts receivable | — | — | — | — | — |
| Purchases of investments | $22.3M | $25.0M | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding VTGN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-30 to 2026-06-30
Recent transactions
- Most recent: Adler Reid G. (Chief Legal Officer) — Grant / award of 36,818 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Adler Reid G. | Chief Legal Officer | Grant / award | 2026-06-30 | 36,818 |
| Tressler Nick B. | Chief Financial Officer | Grant / award | 2026-06-30 | 11,712 |
| Singh Shawn | President and CEO | Grant / award | 2026-06-30 | 36,818 |
| Prince Joshua S. | Chief Operating Officer | Grant / award | 2025-12-31 | 4,386 |
| Anderson Cynthia Lynn | CHIEF FINANCIAL OFFICER | Grant / award | 2025-06-30 | 6,617 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Adler Reid G. | Chief Legal Officer | Grant / award | 36,818 | $0.19 |
| 2026-06-30 | Tressler Nick B. | Chief Financial Officer | Grant / award | 11,712 | $0.19 |
| 2026-06-30 | Singh Shawn | President and CEO | Grant / award | 36,818 | $0.19 |
| 2025-12-31 | Prince Joshua S. | Chief Operating Officer | Grant / award | 4,386 | $0.56 |
| 2025-06-30 | Prince Joshua S. | Chief Operating Officer | Grant / award | 4,882 | $1.70 |
| 2025-06-30 | Adler Reid G. | Chief Legal Officer | Grant / award | 7,541 | $1.70 |
| 2025-06-30 | Anderson Cynthia Lynn | CHIEF FINANCIAL OFFICER | Grant / award | 6,617 | $1.70 |
| 2025-06-30 | Singh Shawn | President and CEO | Grant / award | 7,541 | $1.70 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:42 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-09-25 | 8-K | 2026-09-25 | View on SEC.gov → |
| 2026-09-24 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-31 | 4 | 2026-07-29 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about VTGN (VistaGen Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Vistagen Therapeutics, Inc. (VTGN) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Yahoo · 2026-10-20 -
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
Yahoo Finance · 2026-09-30 -
2 Falling Stocks Call Traders Are Targeting Today
Yahoo Finance · 2026-09-25 -
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
Yahoo Finance · 2026-09-24 -
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
Yahoo Finance · 2026-09-24 -
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Yahoo Finance · 2026-09-24 -
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Yahoo Finance · 2026-09-22
No headlines in this category right now — try “All”.